MedPath

Genetic Data Collection in Adult Participants to Identify Genetic Variants of Known Importance in Non-alcoholic Steatohepatitis (NASH)

Not Applicable
Terminated
Conditions
Non-alcoholic Steatohepatitis (NASH)
Interventions
Procedure: No Intervention
Registration Number
NCT05423327
Lead Sponsor
Regeneron Pharmaceuticals
Brief Summary

Collection of clinical and genetic data to help identify individuals that carry genetic variants of known importance in Non-alcoholic Steatohepatitis (NASH)

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
5311
Inclusion Criteria

One or more of the following:

  1. A prior diagnosis of NASH with a Clinical Research Network (CRN) fibrosis score of F1 to F4 based on liver biopsy

  2. Evidence of NAFLD by imaging or liver histology as described in the protocol

    • The possible imaging modalities to assess historic evidence of NAFLD may be based on thresholds as described in the protocol
  3. Known high-risk genotype for HSD17B13 (T/T or T/TA) and/or PNPLA3 (C/G,or G/G)

  4. A clinical suspicion of NASH based on presence of 2 or more elements of the metabolic syndrome defined by:

    1. Waistline that measures >35 inches (89 centimeters) for women or >40 inches (102 centimeters) for men
    2. Historic fasting triglycerides >150 mg/dL within the prior 6 months
    3. Historic fasting HDL cholesterol <40 mg/dL in men or <50 mg/dL in women, or on cholesterol-lowering medication within the prior 6 months
    4. Historic fasting blood glucose >100 mg/dL or on diabetes medication within the prior 6 months
    5. Historic blood pressure >130/85 mmHg, or on anti-hypertensive medication within the prior 6 months

Key

Exclusion Criteria
  1. Known history or clinical evidence of drug abuse, within the 12 months before screening. Drug abuse is defined as compulsive, repetitive, and/or chronic use of drugs or other substances with problems related to their use and/or where stopping or a reduction in dose will lead to withdrawal symptoms.
  2. Excessive alcohol intake for ≥3 months during the past year prior to screening (>3 units/day for males and >2 units/day for females is generally considered excessive (unit: 1 glass of wine [approximately 125 mL]=1 measure of spirits [approximately 1 fluid ounce]=½ pint of beer [approximately 284 mL]).
  3. History of liver transplant, current placement on a liver transplant list, or Model for End-stage Liver Disease (MELD) score >12.
  4. History of viral and resolved hepatitis or human immunodeficiency virus (HIV).
  5. Any malignancy within the past 5 years except for basal cell or squamous epithelial cell carcinoma of the skin, or any carcinoma in situ.

Note: Other protocol-defined Inclusion/ Exclusion Criteria apply

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Single Blood DrawNo Intervention-
Primary Outcome Measures
NameTimeMethod
Genotype frequencies of rs738409 in patatin-like phospholipase domain containing 3 (PNPLA3)Day 1
Genotype frequencies of rs72613567 in Hydroxysteroid 17β dehydrogenase 13 (HSD17B13)Day 1
Secondary Outcome Measures
NameTimeMethod
Distribution of fibrosis-4 (FIB-4) scores across participants with different genotypes of rs72613567 in HSD17B13Day 1
Distribution of FIB-4 scores across participants with different genotypes of rs738409 in PNPLA3B13Day 1

Trial Locations

Locations (48)

Southern California Research Center

🇺🇸

Coronado, California, United States

Velocity Clinical Research

🇺🇸

Gardena, California, United States

UCSD Health System

🇺🇸

La Jolla, California, United States

National Research Institute

🇺🇸

Panorama City, California, United States

Clinnova Research Solutions

🇺🇸

Orange, California, United States

FEMZ Clinical Research

🇺🇸

Redondo Beach, California, United States

Inland Empire Liver Foundation

🇺🇸

Rialto, California, United States

Precision Research Institute, Llc

🇺🇸

San Diego, California, United States

San Fernando Valley Health Institute

🇺🇸

West Hills, California, United States

Integrity Clinical Research, LLC

🇺🇸

Doral, Florida, United States

Floridian Clinical Research

🇺🇸

Miami Lakes, Florida, United States

Miami Clinical Research

🇺🇸

Miami, Florida, United States

Genoma Research Group, Inc.

🇺🇸

Miami, Florida, United States

US Associates in Research, LLC

🇺🇸

Miami, Florida, United States

Links Clinical Trials

🇺🇸

Miami, Florida, United States

Med Research Of Florida, LLC

🇺🇸

Miami, Florida, United States

IMIC, Inc

🇺🇸

Palmetto Bay, Florida, United States

Revival Research

🇺🇸

Palmetto Bay, Florida, United States

Tandem Clinical Research, LLC

🇺🇸

Marrero, Louisiana, United States

Mercy Medical Center, Inc

🇺🇸

Baltimore, Maryland, United States

University of Pennsylvania - Perelman Center for Advanced Medicine

🇺🇸

Philadelphia, Pennsylvania, United States

Mt. Olympus Medical Research

🇺🇸

Houston, Texas, United States

Synergy Group US LLC

🇺🇸

Houston, Texas, United States

Pioneer Research Solutions, Inc

🇺🇸

Houston, Texas, United States

Epic Medical Research

🇺🇸

Red Oak, Texas, United States

American Research Corporation at The Texas Liver Institute

🇺🇸

San Antonio, Texas, United States

Liver Center of Texas

🇺🇸

Plano, Texas, United States

R & H Clinical Research

🇺🇸

Stafford, Texas, United States

Centro de Diabetes de Curitiba Ltda

🇧🇷

Curitiba, Paraná, Brazil

Hospital de Clínicas de Porto Alegre (HCPA)

🇧🇷

Porto Alegre, Rio Grande Do Sul, Brazil

Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo

🇧🇷

São Paulo, Brazil

IBPClin-Instituto Brasil de Pesquisa Clínica - CCBR

🇧🇷

Rio de Janeiro, Brazil

Keimyung University Dongsan Hospital

🇰🇷

Dalseo-gu, Daegu, Korea, Republic of

Seoul National University College of Medicine, Seoul National University Bundang Hospital

🇰🇷

Seongnam-si, Gyeonggi-do, Korea, Republic of

Hanyang University Seoul Hospital

🇰🇷

Seoul, Gyeonggi, Korea, Republic of

Chung-Ang University Hospital

🇰🇷

Dongjak-gu, Seoul, Korea, Republic of

Seoul National University Hospital

🇰🇷

Jongno-gu, Seoul, Korea, Republic of

CEDOPEC - Centro Especializado en Diabetes, Obesidad y Prevención de Enfermedades Cardiovasculares, S.C.

🇲🇽

Miguel Hidalgo, Ciudad De México, Mexico

Grupo Médico Terranova - Hospital Terranova

🇲🇽

Guadalajara, Jalisco, Mexico

Investigación en Salud y Metabolismo S.C / Nutrición Clínica

🇲🇽

Chihuahua, Mexico

Unidad de Atención Médica e Investigación en Salud (UNAMIS)

🇲🇽

Mérida, Yucatán, Mexico

Dr. Federico Rodriguez-Perez MD, Office of

🇵🇷

San Juan, Puerto Rico

Latin Clinical Trial Center

🇵🇷

San Juan, Puerto Rico

VA Caribbean Healthcare System

🇵🇷

San Juan, Puerto Rico

Fundación de Investigación de Diego, Inc.

🇵🇷

San Juan, Puerto Rico

Dr. Paola Mansilla-Letelier MD, Office of

🇵🇷

San Juan, Puerto Rico

Núcleo de Pesquisa Clínica do Rio Grande do Sul Ltda

🇧🇷

Porto Alegre, Rio Grande Do Sul, Brazil

PCR

🇲🇽

Cuautitlán Izcalli, Estado De México, Mexico

© Copyright 2025. All Rights Reserved by MedPath